NCT02133872View on ClinicalTrials.gov

Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 1, 2018

Study Completion Date

November 1, 2018

Conditions
Hypertension
Interventions
DRUG

Minocycline 50mg/d

Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/\> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/\> 5mm Hg BP subjects will receive minocycline 200 mg.

DRUG

Minocycline 100mg/d

Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/\> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/\> 5mm Hg BP subjects will receive minocycline 200 mg.

DEVICE

Minocycline 200mg/d

Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/\> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/\> 5mm Hg BP subjects will receive minocycline 200 mg.

Trial Locations (1)

32610

UF Health Cardiovascular Clinic, Gainesville

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Florida

OTHER

NCT02133872 - Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients | Biotech Hunter | Biotech Hunter